Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE IRBESARTAN versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE IRBESARTAN versus TEVETEN HCT.
HYDROCHLOROTHIAZIDE; IRBESARTAN vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Irbesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the AT1 receptor, blocking vasoconstriction and aldosterone secretion.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Hydrochlorothiazide 12.5-25 mg and irbesartan 150-300 mg orally once daily. Maximum dose: hydrochlorothiazide 25 mg/day; irbesartan 300 mg/day.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment); Irbesartan: 11-15 hours (supports once-daily dosing).
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Renal: 70% (irbesartan, unchanged and metabolites); 95% (hydrochlorothiazide, unchanged). Fecal: 30% (irbesartan).
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination